Breaking News

Advaxis issued the following statement to stockholders: "We have prepared this summary to highlight the starkly different scenarios Advaxis' stockholders face depending on the outcome of the voting at the Company's special meeting of stockholders relating to its proposed merger with Biosight, which was initially held on November 16, 2021 and has been adjourned to December 7, 2021. In short, we believe consummation of the Biosight merger will result in a substantially more favorable outcome for Advaxis stockholders than the alternative. In our view, the merger between Biosight and Advaxis represents a significant opportunity for Advaxis stockholders to participate in a transformational transaction that establishes a stronger biopharma franchise with multiple opportunities ahead. Earlier this month some of Biosight's largest shareholders and other institutional investors have demonstrated their support for the merger by subscribing to a critical round of investment - but this commitment is contingent upon Advaxis stockholders approving the merger proposals to allow for the consummation of the transaction. To reiterate, this funding will not occur unless the merger is approved and consummated. When the following key points are properly considered, we believe the choice is an easy one. We believe the impact to Advaxis stockholders is drastically different if the merger with Biosight is consummated versus it not being consummated as you can see from the following: 1) Approval of the merger proposals and consummation of the transaction: Provides stockholders with an ownership interest in a company with a broader and more diversified pipeline of drug candidates in terms of: Diversity: More shots on goal. Time to market: Biosight's drug candidate is at a more advanced stage of development which brings it closer to potential regulatory approval. Risk Profile: Safety and efficacy data of Biosight's drug in 91 patients treated has been encouraging to date which we believe increases the chances of regulatory approval. Enables the Company to maintain its Nasdaq listing, preserving greater liquidity for all stockholders and enhances opportunity for future capital raising and institutional investment. Creates a better capitalized company with $21 million of recently announced new financing from institutional investors to advance new drug development contingent on the merger closing. 2) If the merger proposals are NOT approved: We believe Advaxis will be in a materially weaker position. Limits the Company's drug development efforts, relegating its pipeline to an early stage, less diverse and riskier prospects. Substantially reduces stockholder liquidity through imminent delisting with no identified near-term catalysts of significance to regain listing compliance. Results in a financially less stable company with diminished capabilities to raise future capital required not only to continue drug development but to simply remain solvent."

Advaxis announced that leading independent proxy advisory firm, Glass Lewis & Co, joins Institutional Shareholder Services, ISS, in recommending that Advaxis stockholders vote "FOR" the stockholder proposals relating to the Company's proposed merger with Biosight. In its report dated November 11, 2021, Glass Lewis stated: "We believe the strategic rationale for the proposed transaction is generally reasonable from the perspective of Advaxis shareholders. We find that the analyses presented by the advisor are reasonable and contain adequate disclosure. In particular, we note from the advisor's Comparable Initial Public Offerings Analysis that the implied value of the proposed consideration for Biosight falls within the fair value range derived by the advisor using pre-money equity values observed in seven IPOs involving Phase 2 companies without completing a crossover financing and well below the range derived using equity values observed in 12 IPOs involving Phase 2 companies with a focus on oncology... Based on the forgoing factors and the support of the board, we believe the proposed transaction is in the best interests of shareholders."

Biosight issued the following statement from its Chairman, Pini Orbach, PhD. "To Advaxis Stockholders: I am reaching out to you to share our excitement over Biosight's proposed merger with Advaxis (ADXS) and explain why we believe the transaction represents a mutually compelling opportunity for both companies as well as their stockholders. We, the Biosight team, have strong conviction in the vast opportunities for our own franchise which is driven by our phase IIb investigational drug, aspacytarabine, that seeks to address unmet medical needs of certain cancer patients by enabling a high-dose antineoplastic drug with minimal systemic toxicity across multiple forms of leukemic cancer. Therefore, we did not enter into a merger agreement lightly and we negotiated what we believe is a fair apportionment of relative value between Biosight and Advaxis... We believe that aspacytarabine's more advanced clinical stage, more robust clinical dataset, and more clear market opportunity provide enhanced visibility for investors. This enhanced visibility allows investors to construct a viable, long-term, investment thesis for the new, public Biosight Therapeutics. As a result of the merger, Advaxis stockholders will be a part of a more broadly based and well capitalized publicly traded company with a better diversified risk profile. Over the long run, this improved corporate profile may command a reduced cost of capital from institutional investors... Furthermore, Advaxis recently announced that, contingent on the merger closing, the company has received commitments of $21 million in financing necessary to advance its clinical development programs. We now expect the cash balance of the combined company, including this proposed financing, to be at least $70M at the time of merger closing which we expect will take us into the second half of 2023 and would allow us to potentially achieve key clinical milestones with aspacytarabine that we believe will create greater short- and long-term value for all stockholders. In our view, it is clear that the proposed merger of Advaxis and Biosight is preferable for all parties involved, as we believe it represents a superior outcome compared to both a stand-alone Advaxis and stand-alone Biosight. It has the potential to create a Win/Win/Win scenario as it benefits both Advaxis and Biosight and their respective stockholders, and may benefit cancer patients desperately in need of alternative treatments not currently available."

Advaxis issued the following statement to stockholders: "I am writing to provide you with information and resources to help demonstrate the compelling benefits of the Company's proposed merger with Biosight. We believe that the proposed Biosight transaction can generate significant value for Advaxis stockholders. The combined company will be better capitalized and well-positioned to advance a broader portfolio of drug candidates aimed at addressing both liquid and solid tumors. The closing of the transaction is contingent upon, among other things, the approval of Advaxis' stockholders at the Special Meeting scheduled for November 16, 2021. Please watch this video, also available on the Advaxis website, which we prepared to provide you with some additional important information about the merits of the Biosight transaction to help inform your voting decision. In addition, a leading independent proxy advisory firm, ISS, has recommended that stockholders vote "FOR" all of the proposals at the special meeting, citing Advaxis' "thorough strategic review process" and "logical" rationale for the Biosight transaction. These items are described in detail in the proxy materials the Company has sent to our stockholders. We strongly urge you to vote today in support of the merger and related proposals. Thank you for attention to this matter."

Advaxis announced that leading proxy advisory firm Institutional Shareholder Services, ISS, issued a report on November 1, 2021, recommending that Advaxis stockholders vote "FOR" the merger of the Company with Biosight and recommends voting "FOR" all proposals, at the Company's Special Meeting scheduled for November 16, 2021. The ISS recommendation stated, "The board ran what appears to have been a thorough strategic review process, corresponding with over 200 potential counterparties on a broad variety of transaction types, and no competing offers have been publicly disclosed since announcement. The strategic rationale also appears logical, as it will diversify the pipeline of product candidates, and is expected to result in a combined company with a more stable financial position. In light of these factors, support for the proposal is warranted." In addition, in recommending stockholders vote "FOR" the reverse stock split proposal, ISS highlighted "the reverse split may enable the company to maintain listing of its common stock on the Nasdaq Capital Market."